PLCG2 and telomere syndrome: In recent years, clinical researchers have attempted to improve NK cell activity using various anti-tumor approaches and have decreased the number of resting NK cells, which are disadvantageous to tumor suppression.[65,66] In addition, M0 macrophage infiltration in the TME has been proved to be a marker of poor prognosis in some tumors.[14,67] Thus, these results indicate that the expression of PLCG2 influenced activation of the immune component within the TME in STS.